Document:

<PAGE>
                                                                   EXHIBIT 10.84

                        SUPPLY AND DISTRIBUTION AGREEMENT

         THIS SUPPLY AND DISTRIBUTION AGREEMENT is effective as of the 24th day
of November, 2003, between Pfizer Inc., a corporation organized and existing
under the Laws of Delaware and having its principal office at 235 East 42nd
Street, New York, New York 10017 (hereinafter referred to as "PFIZER") and Andrx
Corporation, a corporation organized and existing under the Laws of Delaware and
having its principal office at 2915 Weston Road, Weston, Florida 33331
(hereinafter called "DISTRIBUTOR").

                                   WITNESSETH

         WHEREAS, Pfizer and its Affiliates are seeking NDA Approval (as defined
below) of the Product (as defined below);

         WHEREAS, Pfizer wishes to appoint Distributor as its exclusive
distributor for the Product in the United States of America, including its
territories and possessions (hereinafter referred to as the "TERRITORY"), and
Distributor is willing to accept such appointment in accordance with and subject
to the terms and conditions hereinafter appearing.

         NOW, THEREFORE, in consideration of the premises and mutual covenants
herein contained, the parties hereto agree as follows:

                                   ARTICLE I
                                   DEFINITIONS

         SECTION 1.01. DEFINITIONS. As used in this Agreement, the following
capitalized terms shall have the following meanings:

"ADJUSTED DETAILING REQUIREMENT" has the meaning set forth in SECTION 7.01(C).

"ADVERSE DRUG EXPERIENCE REPORT" means any oral, written or electronically
transmitted report of any "adverse drug experience" (as defined in the FD&C Act,
including, but not limited to, 21 C.F.R. 314.80 or 312.32), associated with the
use of doxazosin mesylate (including the Product).

"ALZA" has the meaning set forth in SECTION 11.02(A).

"ANDA" means an "abbreviated new drug application" (as defined in Section
201(aa) of the FD&C Act).

"AFFILIATE" means any Person that directly or indirectly controls, is controlled
by or is under common control with Pfizer or Distributor, as the case may be,
but only for so long as said control shall continue. As used herein, the term
"control" means possession of the power to direct or cause the direction of the

<PAGE>

management and policies of a Person whether by contract or otherwise. For the
avoidance of doubt, neither Pfizer, on the one hand, nor Distributor, on the
other hand, shall be considered an Affiliate of the other.

"CGMP" means current good manufacturing practices as defined in Title 21 of the
C.F.R. Parts 210 ET SEQ., as amended from time to time.

"CODE" means the Code on Interactions with Healthcare Professionals promulgated
by the Pharmaceutical Research and Manufacturers of America (PhRMA), the
American Medical Association Guidelines on Gifts to Physicians and the Office of
Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers,
as any of the foregoing may be amended from time to time.

"COMMERCIALLY REASONABLE EFFORTS" means the efforts that a party shall use in
carrying out its obligations under this Agreement, which efforts, except as
provided herein, shall be the same as those efforts a party would use with
respect to its own pharmaceutical products which are of similar importance to
the Products taking into account market potential, past performance, economic
return and competitive market conditions in the therapeutic area, all as
measured by the facts and circumstances at the time such efforts are due.

"COA" has the meaning set forth in Section 9.08(a).

"COMPETING PRODUCT" has the meaning set forth in Section 2.02(a).

"CONFIDENTIAL INFORMATION" means, with respect to any party (the "disclosing
party"), any information relating to the disclosing party, the Product or the
disclosing party's business (including, but not limited, to technical
information, research, personnel, financial, marketing, strategic or other
information) that is disclosed in writing to the other party ("receiving party")
in the course of the parties' negotiation of or performance under this Agreement
(it being understood that if any information is disclosed verbally, in order for
that information to be considered "Confidential Information," the disclosing
party must notify the receiving party in writing that the information is
"Confidential Information" within thirty (30) days after disclosure), but shall
not include information that: (a) the receiving party knew, owned or controlled
prior to receipt from the disclosing party; (b) is or becomes public through no
fault of the receiving party or any Affiliate thereof; (c) is developed by the
receiving party independent of any disclosure from the disclosing party or (d)
the receiving party obtains from a third party not under a confidentiality
obligation to the disclosing party.

"CONTRACT YEAR" means each twelve (12) month-period commencing on the date of
NDA Approval and each anniversary of the date of NDA Approval.

"COVERED ACTIVITY" has the meaning set forth in Section 10.03(c)(i).

"DDMAC" has the meaning set forth in SECTION 9.02.

"DISTRIBUTOR" has the meaning set forth in the recitals hereto.

"DISTRIBUTOR LOGO" has the meaning set forth in SECTION 11.01(B).

* Filed under application for confidential treatment.

                                       2
<PAGE>

"FD&C ACT" has the meaning set forth in SECTION 7.03(G).

"FDA" has the meaning set forth in SECTION 7.03(G).

"FIRM ORDER" means a firm, binding, written order for Product, specifying
quantities and delivery schedules. Firm Orders must be in full lot size
quantities as described in Exhibit A, provided, however, if FDA permits printing
on 4mg and 8mg Systems that is identical to the printing permitted on 4mg and
8mg Systems outside the Territory, Launch Date Firm Order and the Firm Orders
submitted during the first six (6) months after launch may be in half lot sizes
for 4mg and/or 8mg Systems.

"FORCE MAJEURE" means any event beyond the reasonable control of a party or its
Affiliates and whose effect such Person could not reasonably have avoided,
including, but not limited to, acts of God, fires, floods, wars, acts of
terrorism, sabotage, strike, change of Laws. Any party asserting its inability
to perform any obligation hereunder for any such contingency shall promptly
notify the other party of the existence of such contingency and shall use
Commercially Reasonable Efforts to commence its performance of such obligation
as soon as commercially practicable.

"GOVERNMENTAL OR REGULATORY AUTHORITY" means any court, tribunal, arbitrator,
agency, commission, official or other instrumentality of any federal, state,
county, city or other political subdivision, domestic or foreign, including, but
not limited to, the FDA.

"INDEMNIFIED PARTY" has the meaning set forth in SECTION 15.04.

"INDEMNIFYING PARTY" has the meaning set forth in SECTION 15.04.

"INDEPENDENT ACCOUNTANT" has the meaning set forth in SECTION 6.01.

"INDIRECT LOSSES" means any damages or other losses involving, but only to the
extent of, any loss of profits, diminution in value, or incidental, indirect,
consequential, special or punitive damages.

"LAWS" means all laws, statutes, rules, regulations, ordinances, Codes, and
other pronouncements having the effect of law of any government or Governmental
or Regulatory Authority.

"LOSSES" means any and all claims, liabilities, losses, damages, fees,
penalties, judgments, awards, interest, costs and expenses (including, but not
limited to, reasonable attorneys' fees and expenses) owed directly to either
party to this Agreement or any Affiliate thereof. Notwithstanding the foregoing,
Losses shall not include Indirect Losses.

"MARKETING PLAN" has the meaning set forth in SECTION 7.02(A).

"MINIMUM DETAILING REQUIREMENT" has the meaning set forth in SECTION 7.01(A).

"MSDS" has the meaning set forth in Section 9.08(a).

* Filed under application for confidential treatment.

                                       3
<PAGE>

"NDA" means Pfizer's FDA New Drug Application 21-269 and any supplements
thereto.

"NDA APPROVAL" means Pfizer's receipt of FDA approval of the NDA with
manufacturing specifications either (i) the same as will be provided in Pfizer's
response to the FDA regarding the NDA or (ii) otherwise acceptable to Pfizer as
determined in its sole discretion, provided that Pfizer gives Distributor notice
of such acceptance within thirty (30) days of receipt of such FDA final
marketing approval (in which case NDA Approval shall be deemed to be received at
the time of Pfizer giving such notice).

"NET SALES" means the aggregate gross sales of the Product by Distributor and
its Affiliates in the Territory when received by customer, MINUS: [xxxx]*.

"PDMA" has the meaning set forth in Section 3.08(c).

"PER SYSTEM FEE" has the meaning set forth in SECTION 5.03.

"PERSON" means any natural person, corporation, partnership, joint venture,
trust, proprietorship or other entity or organization.

"PFIZER" has the meaning set forth in the recitals hereto.

"PROCEEDINGS" means claims, suits, actions, investigations or proceedings.

"PRODUCT" means prescription pharmaceutical forms (4mg and 8mg) of Cardura(R) XL
(doxazosin mesylate) extended release tablets.

"PRODUCT LIABILITY CLAIM" shall mean any third party Proceedings involving any
actual or alleged death or bodily injury arising out of or resulting from the
use of the Product sold in the Territory.

"PROMOTIONAL MATERIALS" has the meaning set forth in SECTION 7.03(A).

"SERIOUS ADVERSE DRUG EXPERIENCE REPORT" means any Adverse Drug Experience
Report that involves an adverse drug experience or any other event which would
constitute a "serious" adverse drug experience under the FD&C Act, including,
but not limited to, 21 C.F.R 314.80 or 312.32.

"SHORTFALL CONTRACT YEAR" has the meaning set forth in Section 7.01(c).

"SHORTFALL DETAILS" has the meaning set forth in Section 7.01(c).

"SPECIFICATIONS" shall mean all product, regulatory, manufacturing, quality
control and quality assurance procedures, processes, standard instructions and
specifications comprising the NDA Approval.

"STATE" has the meaning set forth in SECTION 7.03(C).

"SUPPLY FAILURE NOTICE" shall have the meaning set forth in Section 3.05(b).

* Filed under application for confidential treatment.

                                       4
<PAGE>

"SYSTEM" shall mean a 4mg or 8mg extended-release tablet of the Product.

"TERM" has the meaning set forth in SECTION 13.01.

"TERRITORY" has the meaning set forth in the recitals hereto.

"TRADEMARK" has the meaning set forth in SECTION 11.01(A).

                                   ARTICLE II
                       APPOINTMENT - EXCLUSIVE DISTRIBUTOR

         SECTION 2.01. APPOINTMENT. Pfizer hereby appoints Distributor as its
exclusive Distributor in the Territory during the Term of this Agreement to buy
and resell for Distributor's own account, to solicit orders for, to distribute,
detail and promote the Product. Distributor hereby accepts such appointment in
accordance with the terms of this Agreement.

         SECTION 2.02. (a) Pfizer shall notify Distributor upon the receipt of
any notice of (i) an AB rated ANDA for a Cardura(R) XL product or (ii) an
application described in Section 505(b)(2) of the FD&C Act for a doxazosin
mesylate extended release product relating to Cardura(R) XL (in either case, a
"Competing Product"). Thereafter, the parties shall jointly monitor the FDA
approval process for the Competing Product(s). Prior to the anticipated date of
FDA approval of a Competing Product, Pfizer shall determine if it desires to
have its Product compete in the Territory with the Competing Product as a
generic or other non-branded product in the Territory, and shall notify
Distributor, in writing, of such determination. Except as set forth in Section
2.02(b) below, if Pfizer desires to have the Product sold as a generic or
non-branded doxazosin mesylate extended release product in the Territory, Pfizer
will agree to allow Distributor to become Pfizer's exclusive distributor for
Pfizer's generic or non-branded product in the Territory (the "Option") on terms
substantially similar to those set forth in the form of the Agreement attached
hereto as Exhibit B, which will allow Distributor to launch such Product into
the Territory either simultaneously with or shortly after the launch of the
Competing Product, and provides for a transfer price to be paid to Pfizer
[xxxx]* of net sales (as such term is to be defined in the generic agreement)
for an [xxxx]*. The Option may be exercised and accepted by Distributor by
providing Pfizer with written notice of such exercise and acceptance, together
with an executed counterpart of the signature page to the form of Agreement
attached hereto as Exhibit B, within ten (10) days of the date of its receipt of
Pfizer's Option notice to Distributor pursuant to the preceding sentence. If
such documents are not received by Pfizer within such time period, then the
Option shall be deemed to have not been exercised and accepted and shall lapse
at the expiration of such time period.

         (b) Notwithstanding the provisions of subsection (a) above, Distributor
shall not have the Option described in subsection (a) above if (x) a Person
files an application for a Competing Product and (y) ALZA or Pfizer, in its sole
discretion, brings a Proceeding against such Person and resolves such Proceeding
by, among other things, granting to such Person the exclusive right to sell and
distribute Pfizer's non-branded doxazosin mesylate extended release product in
the Territory.

* Filed under application for confidential treatment.

                                       5
<PAGE>

                                  ARTICLE III
                        ORDERS AND MANUFACTURE OF PRODUCT

         SECTION 3.01. ORDERS AND TERMS OF SALE. Distributor and its Affiliates
shall have the sole and exclusive right and authority to: (i) receive, accept
and fill orders for the Product; (ii) control invoicing, order processing and
collection of accounts receivable for Product sales; (iii) record Product sales
in their books of account; (iv) establish and modify the commercial terms and
conditions with respect to the sale and distribution of the Product, including
the price at which the Product will be sold and whether any discounts, rebates
or other deductions should be made, paid or allowed; and (v) enter into discount
or rebate contracts for the Product with managed care entities (including PBMs,
HMOs and other managed care businesses) or other purchasers or reimbursers of
the Product, in each case subject to applicable Laws.

         SECTION 3.02. MISDIRECTED ORDERS. If, for any reason, Pfizer receives
written orders for the purchase of the Product in the Territory, Pfizer shall
forward such orders to Distributor as soon as practicable.

         SECTION 3.03. MANUFACTURING AND FORECASTS.

         (a) Pfizer and its Affiliates shall have the sole and exclusive
authority and responsibility for the manufacture of the Product. Distributor
shall not be permitted to manufacture, nor shall it acquire any rights to any
know-how or technical information with respect to the manufacture, of the
Product.

         (b) Pfizer will provide to Distributor quantities of 4mg and 8mg
Systems of Product (both commercial quantities and samples) set forth as the
"Launch Date Firm Order" in Exhibit A as soon as practicable following the date
of the NDA Approval. In addition, Distributor's first two (2)-year rolling
forecast of orders for 4mg and 8mg Systems (both commercial quantities and
samples) also is set forth in Exhibit A. On or before three (3) months prior to
the start of each calendar quarter, Distributor shall provide to Pfizer a
rolling quarterly forecast of its anticipated 4mg and 8mg Product requirements
for the following [xxxx]*. In addition, at least three (3) months prior to the
start of each calendar quarter, Distributor will provide Pfizer with a Firm
Order for each of the 4mg and 8mg Systems of Product for such quarter (listing
separately commercial quantities and samples), which must be no less than
[xxxx]* (subject to the minimum purchase amounts below), or greater than [xxxx]*
of the amount forecast in the most recent prior rolling forecast.
Notwithstanding the foregoing, Distributor shall not be required to meet these
requirements for the calendar quarter immediately following the calendar quarter
in which a Competing Product enters the market.

         (c) Distributor shall purchase hereunder the following minimum
aggregate commercial quantities of 4mg and 8mg Systems of Product in each
Contract Year:

           [xxxx]*

         If in any Contract Year Distributor orders at least the minimum
aggregate commercial quantities for such year as set forth above and Pfizer
fails to deliver such minimum aggregate commercial quantities, Distributor shall

* Filed under application for confidential treatment.

                                       6
<PAGE>

be relieved of its obligation in such Contract Year solely to the extent by
which Pfizer's deliveries are less than such minimum aggregate commercial
quantities. In addition, if (x) a Person files an application for a Competing
Product and (y) ALZA or Pfizer, in its sole discretion, brings a Proceeding
against such Person and resolves such Proceeding by, among other things,
granting to such Person the exclusive right to sell and distribute Pfizer's
non-branded doxazosin mesylate extended release product in the Territory prior
to the end of the 3rd Contract Year and (z) such Person commences commercial
sales of the Competing Product prior to the end of the 3rd Contract Year, then
Distributor shall be relieved of its minimum purchase obligations on a pro rata
basis for the Contract Year which the commercial sale of the Competing Product
commences and for all subsequent Contract Years.

         SECTION 3.04. ACCEPTANCE OF ORDERS. Distributor shall submit Firm
Orders to Pfizer against the forecasts via facsimile transmission or e-mail, and
Pfizer shall confirm all of Distributor's Firm Orders by facsimile transmission
or e-mail within seven (7) days after receipt of such Firm Orders.

         SECTION 3.05. SUPPLY OBLIGATIONS. (a) All of Pfizer's obligations to
supply quantities of the Product pursuant to SECTION 3.03 shall be contingent
upon its receipt of NDA Approval. Thereafter, notwithstanding anything herein to
the contrary, Pfizer shall use its Commercially Reasonable Efforts to supply the
Product, having expiration dating of at least [xxxx]* at the time of delivery to
Distributor, in sufficient quantities to meet all demands for the Product in the
Territory in accordance with the then current Firm Order and the procedures set
forth in SECTION 3.03.

         (b) Pfizer shall deliver Product to Distributor pursuant to Purchase
Orders no later than ten (10) days after Distributor's requested delivery dates.
Pfizer shall promptly notify Distributor in writing if for any reason Pfizer has
reason to believe that it will be unable to supply on a timely basis (in
accordance with Pfizer's normal and customary practices) the quantities of
Product ordered pursuant to SECTION 3.03 above (a "Supply Failure Notice").

         (c) If Pfizer has delivered a Supply Failure Notice to Distributor
pursuant to subsection (b), then Pfizer will as soon as practicable after the
delivery of the Supply Failure Notice, supply Distributor pursuant to the
provisions of the following sentence until such time Pfizer is once again
capable of supplying the quantities of Product ordered by Distributor. [xxxx]*

         (d) [xxxx]*Notwithstanding the foregoing, Distributor will not be
entitled to the benefits of this Section 3.05(d) if, at the time it placed the
first Firm Order which was not filled during any applicable period, it was not
in compliance with the provisions of Section 5.04. If, following Pfizer's
failure to supply Product, Distributor receives backorders from any of the three
major wholesalers, Distributor promptly shall so inform Pfizer in writing and,
in connection therewith, also certify in writing as to its compliance with
Section 5.04 as set forth in this subsection (d).

         (e) For the avoidance of doubt, it is understood that Pfizer's
obligations to expend its Commercially Reasonable Efforts pursuant to Section
3.05(a) shall not require Pfizer to expand manufacturing capacity at its plant
in Brooklyn, New York (where the Product is to be manufactured), materially
interfere with its existing commitments to third parties to produce products at

* Filed under application for confidential treatment.

                                       7
<PAGE>

its plant in Brooklyn, New York, nor to license, contract or otherwise arrange
for any other plants to manufacture the Product.

         (f) Except as set forth in Section 3.05(d), Distributor's sole remedy
in the event Pfizer fails to supply Product in accordance with Firm Orders
furnished to Pfizer in accordance with the terms of this Agreement shall be to
bring suit to recover its Losses in the event of a breach of Section 3.05(c) (if
and to the extent Pfizer fails to comply with its obligations thereunder and
Distributor is damaged by reason of its resulting inability and failure to fill
bona fide customer orders). Distributor hereby waives any and all other claims
(including, without limitation, claims of breach of contract) and remedies
(including the remedy of termination of this Agreement) that it might otherwise
have available to it upon Pfizer's failure to supply the quantities of Product
ordered by Distributor hereunder on a timely basis.

         SECTION 3.06. DELIVERY AND TITLE. Each shipment of Product will be
shipped to a single destination designated by Distributor. Title and risk of
loss or damage to Product for each shipment shall pass from Pfizer to
Distributor at the shipping dock at Pfizer's plant in Brooklyn, New York, F.O.B.

         SECTION 3.07. MANUFACTURE IN COMPLIANCE WITH SPECIFICATIONS. Pfizer
will manufacture, package, label, store and ship the Product in accordance with
the Specifications set forth in the NDA as such NDA may be amended from time to
time and, as to tablet printing designation and label copy, in accordance with
Distributor's reasonable instructions to Pfizer. Pfizer shall promptly advise
Distributor of any new instructions or specifications required by the FDA or the
FFDCA. In the event Pfizer cannot reasonably manufacture Product in accordance
with Distributor's instructions and the Specifications, Pfizer shall so advise
Distributor.

         SECTION 3.08. SAMPLES. (a) Following launch of the Product and in
support of Distributor's promotional activities hereunder, Pfizer shall provide
Distributor with Product samples as set forth in Section 3.03 above.

         (b) The price for each Product sample initially shall be [xxxx]* per
System. The price of Product samples shall be adjusted effective as of each
January 1st following NDA Approval by such percentage increase in the Producer
Price Index as published by the United States Department of Labor, Bureau of
Labor Statistics (the "PPI") over the immediately preceding 12 month period. The
price adjustment under this Section 3.08(b) shall be notified to Distributor not
later than June 30th of each year and shall be retroactively effective to
January 1st of that same year and shall apply to all firm orders for samples
received on or after said January lst. In the event that Pfizer fails to provide
notice of any PPI increase by June 30th of a given year, any such increase shall
only be effective as of the date such notice is actually given and shall only
apply to Firm Orders received on or after such date. If the PPI is not available
for any period, the most similar available index shall be used.

         (c) Distributor shall store and distribute samples in full compliance,
and otherwise fully comply, with all applicable Laws, including the requirements
of the Prescription Drug Marketing Act of 1987, as amended (the "PDMA").
Distributor will maintain those records required by the PDMA and all other Laws
with respect to the Product samples. Distributor shall be responsible for the
filing of any necessary reports to FDA in connection with the PDMA with respect

* Filed under application for confidential treatment.

                                       8
<PAGE>

to the samples allocated to it. Section 3.06 shall be applicable to samples.

                                   ARTICLE IV
               THIRD PARTY OFFERS OR RE-SALE OUTSIDE THE TERRITORY

         SECTION 4.01. THIRD PARTY OFFERS. Distributor shall purchase the
Product only from Pfizer or Pfizer's Affiliates and shall report to Pfizer any
offers by third parties to supply the Product or any other pharmaceutical
products purporting to be products of Pfizer to Distributor for sale in the
Territory or elsewhere.

         SECTION 4.02. RESALE OUTSIDE THE TERRITORY. Distributor shall not
solicit orders for, nor resell, distribute or promote the Product outside of the
Territory or to any purchaser or distributee that Distributor anticipates, or
reasonably should anticipate, intends to utilize, resell, distribute or promote
the Product outside the Territory.

         SECTION 4.03. INDEMNIFICATION. Distributor shall indemnify Pfizer and
its Affiliates from and against any and all Losses arising from the re-sale of
the Product outside the Territory or re-export of the Product from the
Territory.

                                   ARTICLE V
                                TERMS OF PAYMENT

         SECTION 5.01. UP FRONT FEE. Distributor shall pay Pfizer an up-front,
non-creditable fee of [xxxx]* on the date hereof, which will be refunded only if
this Agreement is terminated by Pfizer pursuant to SECTION 13.02(A) or
Distributor pursuant to SECTION 13.03(A).

         SECTION 5.02. NDA APPROVAL FEE. Distributor shall pay Pfizer a
non-creditable fee of [xxxx]*within thirty (30) days of Distributor receiving
notice from Pfizer that it has received NDA Approval, provided that the approved
Product meets all or substantially all of the criteria for each claim set forth
on Attachment I hereto and Pfizer complies with all conditions associated with
NDA Approval. The [xxxx]* fee will be nonrefundable.

         SECTION 5.03. PER SYSTEM FEE. (a) [xxxx]*.

         (b) In the event that the quotient obtained by dividing Net Sales by
the number of commercial Systems sold (the "NET SALES PER SYSTEM") in any
calendar quarter experiences an independently verifiable decrease of at least
[xxxx]* from the previous calendar quarter as a result of Extraordinary Market
Events (as hereinafter defined), the parties shall in good faith attempt to
determine a new reduced Per System Fee for the Products available for commercial
sale. In the absence of such agreement, the Per System Fee, effective as of the
start of the calendar quarter following which the Net Sales Per System
experienced the requisite decrease, shall be reduced by a percentage equal to
the Net Sales Per System percentage decreases from the previous calendar quarter
as a result of the Extraordinary Market Events. Extraordinary Market Events
shall be limited to (i) reductions (in a calendar quarter from the previous
calendar quarter) in the Federal Supply Schedule (FSS) (or any successor
schedule that will reflect the effective price paid for brand pharmaceuticals by
governmental programs taking into account the manufacturer rebates received by
States and/or other governmental entities) of each of the [xxxx]* (or if there
is not [xxxx]* such products, such lower number) highest selling branded
products (by volume) at such time(excluding the Product), indicated for benign

* Filed under application for confidential treatment.

                                       9
<PAGE>

prostate hyperplasia (BPH), and/or (ii) governmentally required changes in the
rebates, discounts, allowances, reimbursements or other changes, such as price
controls, in the manner in which pharmaceutical products are presently sold to
customers, including but not limited to the broader non-state or federal markets
or the amounts required to be paid to state and/or other governmental agencies,
such as the Department of Veteran Affairs. The reduction of [xxxx]* in the Net
Sales Per System to Distributor may result from either (i) or (ii) or a
combination of (i) and (ii) in such quarter from the previous calendar quarter,
provided however, that if the cause of the price reduction is reflected in both
(i) and (ii), only one of such reductions shall be included when determining
whether the [xxxx]* threshold has been met. Published sources such as the FSS or
the Medicaid Rebate Net Price program (in the case of clause (ii)) or data
generated by third party vendors such as IMS Health or NDC Health (in the case
of clause (i), may serve as an independently verifiable source. Distributor may
so exercise its right to a price reduction pursuant to this subsection (b) no
more than once during the Term. If there is a reduction of the Per System Fee
pursuant to this subsection (b) and there are subsequent increases in the Net
Sales Per System received by Distributor during the Term, then the Per System
Fee shall be proportionately increased upon each subsequent increase in Net
Sales Per System, but not above [xxxx]* per System, subject to increase pursuant
to the provisions of Section 7.01(c).

         (c) In the event Distributor believes that the provisions of this
subsection (b) are applicable, it will promptly inform Pfizer in writing of its
belief and furnish Pfizer calculations of the Net Sales Per System for the
applicable calendar quarters, along with copies of the published sources which
support such belief. In addition, following any reduction of the Per System Fee
pursuant to this subsection (b), Distributor shall promptly notify Pfizer of any
subsequent increase in the amount it charges Per System during the Term.

         SECTION 5.04. MINIMUM INVENTORY. During the Term, at all times from and
after the date of the initial delivery to be made pursuant to the Launch Date
Firm Order, Distributor will keep on hand inventories of the Product that will
be sufficient to meet [xxxx]* demand from customers for the Product based upon
Distributor's good faith estimates of future sales. At the end of each calendar
month, Distributor will determine and provide Pfizer with the quantities of each
system of the Product sold by Distributor during such calendar month.
Additionally, Distributor will provide Pfizer with ending inventory quantities
at the end of each calendar month. Such information will be set forth in a
report furnished by the Distributor to Pfizer within [xxxx]* days after each
calendar month.

         SECTION 5.05. MANNER OF PAYMENTS. All sums due under this Agreement
shall be payable in United States dollars by bank wire transfer of immediately
available funds to such bank account(s) as Pfizer shall designate.

         SECTION 5.06. INTEREST ON LATE PAYMENTS. If Distributor shall fail to
make a timely payment pursuant to this ARTICLE V, interest shall accrue on the
past due amount at a rate equal to the prime rate effective for the date such
payment is due, as published in the Wall Street Journal, [xxxx]* effective for

* Filed under application for confidential treatment.

                                       10
<PAGE>

the first date on which the payment was delinquent for up to [xxxx]* such
payment is delinquent, then [xxxx]* thereafter, and calculated through and
including the date of payment on the basis of 360-day years.

                                   ARTICLE VI
                            RECORDS AND AUDIT RIGHTS

         SECTION 6.01. For each Contract Year, Distributor shall keep such
records of details as are necessary to determine accurately the number of
details performed by Distributor pursuant to SECTION 7.01 below. Such records
shall be retained by Distributor and shall be made available only for
inspection, review and audit, at any time during the applicable Contract Year
and for three years thereafter, at the request and, except as provided below,
expense of Pfizer, by a nationally recognized independent certified public
accountant with expertise in the pharmaceutical industry that is selected by
Pfizer and reasonably acceptable to Distributor (the "INDEPENDENT ACCOUNTANT")
for the sole purpose of verifying the number of details performed by Distributor
pursuant to this Agreement. Distributor acknowledges and agrees that KPMG is
suitable to serve as the Independent Accountant. Such audits may not be
performed more than twice per Contract Year. The Independent Accountant shall
not reveal to Pfizer the details of such review, except for such information as
is required to be disclosed under this Agreement, and shall be subject to
confidentiality obligations consistent with the provisions of SECTION 14.01
hereof. The Independent Accountant shall prepare a report of its findings and
conclusions, which report shall be final and binding on the parties hereto. All
costs and expenses related to such audit shall be borne by Pfizer; PROVIDED that
if the number of details performed by Distributor varies by [xxxx]* or more than
the number reported by Distributor, Distributor shall pay such costs and
expenses within [xxxx]* after it receives an invoice from Pfizer regarding the
same.

                                  ARTICLE VII
                      PROMOTIONAL ACTIVITIES AND MATERIALS

         SECTION 7.01. MARKETING, PROMOTIONAL AND DETAILING EFFORTS.

         (a) Distributor shall deploy such of its sales forces and other
resources to market, promote and detail the Product in the Territory in
accordance with the terms of this Agreement and the then current Marketing Plan.
In conducting such marketing, promotion and detailing, Distributor shall use its
reasonable commercial efforts and diligence, consistent with accepted
pharmaceutical industry business practices and in compliance with all applicable
Laws. Distributor shall perform a minimum of [xxxx]* self-reported details per
Contract Year (or proportional amount thereof in the event of a partial Contract
Year) (the "Minimum Detailing Requirement"). Notwithstanding the preceding
sentence, if Pfizer fails to supply Product ordered by Distributor in accordance
with the provisions of this Agreement and such failure makes it not commercially
feasible for Distributor to fulfill the Minimum Detailing Requirement, then
Distributor shall be relieved of its obligation during the period of the supply
failure solely to the extent of the number of details below the Minimum
Detailing Requirement that Distributor was not able to perform by reason of

* Filed under application for confidential treatment.

                                       11
<PAGE>

Pfizer's failure to supply. In addition, Distributor's obligation to perform the
Minimum Detailing Requirement shall be suspended for Contract Years beginning
after the date of launch of a Competing Product (with Distributor's obligation
for the Contract Year in which such launch occurs pro rated pursuant to the
provisions above). All details performed by or on behalf of Distributor
hereunder shall be performed by Distributor's own sales representatives, and
Distributor shall not use any contract sales force for such purpose unless
approved by Pfizer in advance.

         (b) Distributor shall bear all of the costs and expenses incurred in
connection with its marketing, promotional and detailing efforts, including, but
not limited to, the costs and expenses of its sales representatives.

         (c) [xxxx]*.

         SECTION 7.02. MARKETING PLANS.

         (a) Distributor shall be responsible for developing a comprehensive and
detailed annual plan and budget for the marketing, promotion and detailing of
the Product in the Territory (the "MARKETING PLAN") for each Contract Year.
Distributor's initial draft Marketing Plan for the first Contract Year is
attached hereto as Exhibit C, and subsequent Marketing Plans shall be submitted
by the Distributor to Pfizer no later than February 28, 2004 for the first
Contract Year, and no later than [xxxx]* prior to the start of each subsequent
calendar year. Pfizer shall have the right to comment on the Marketing Plan, and
Distributor shall make changes to such plan as may be reasonably requested by
Pfizer.

         (b) Subject to the provisions of this Agreement, each Marketing Plan
shall describe in reasonable detail how the Product is to be promoted and
detailed in the Territory during the Contract Year to which that Marketing Plan
relates and shall consist of:

                  [xxxx]*.

         SECTION 7.03. MARKETING, ADVERTISING, PROMOTIONAL AND EDUCATIONAL
MATERIALS.

         (a) Distributor shall create and develop marketing, advertising,
promotional, educational and communication materials for the Product for
distribution to third parties (including medical professionals) and to
Distributor's sales force (the "PROMOTIONAL MATERIALS") consistent with the
terms of the final Marketing Plans.

         (b) Subject to the terms of this Section and SECTION 11.01, Distributor
shall own all right, title and interest in and to any Promotional Materials,
including all applicable copyrights and trademarks. Distributor hereby grants
Pfizer a non-exclusive, perpetual royalty-free license, with the right to
sublicense to its Affiliates, to display, reproduce, distribute and use
Distributor's Promotional Materials outside the Territory, subject to applicable
Laws.

         (c) Distributor shall be responsible for filing and maintaining all
documentation and other information as required by each and every state and
locality ("STATE") for the purpose of listing the Product on each State's
formulary or other similar authority, and for obtaining such other approvals as
may be necessary to sell the Product in the Territory, at its expense.
Distributor will pay Medicaid and other applicable rebates required by Laws or
contract.

* Filed under application for confidential treatment.

                                       12
<PAGE>

         (d) Distributor shall bear all costs and expenses incurred in
connection with creating, producing, distributing, publishing and otherwise
using the Promotional Materials.

         (e) Distributor covenants that no claims or representations in respect
of the Product or doxazosin mesylate or the characteristics thereof shall be
made by or on behalf of it (by members of its sales force or otherwise) that do
not comply with FDA-approved labeling of the Product or that are not otherwise
in compliance with all applicable Laws and will not take any action that, in the
reasonable opinion of Pfizer, either dilutes the Cardura(R) XL trademark or may
cause damage to Pfizer's sale of doxazosin mesylate (including the Product)
outside the Territory or to Pfizer's reputation, and Pfizer shall have the
reasonable right to require that Distributor withdraw or change any Promotional
Materials if any of the foregoing claims or representations are made or actions
are taken.

         (f) During the Term, Pfizer will not sponsor exhibits or booths at
meetings and symposia directed at promotion of the Product in the Territory.
Distributor will not sponsor exhibits or booths at meetings and symposia
directed at promotion of the Product outside the Territory. To the extent Pfizer
sponsors booths or symposia within the Territory directed at activities outside
of the Territory and Distributor sponsors booths or symposia outside the
Territory directed at activities within the Territory, the parties agree to meet
in good faith to coordinate potential overlapping activities.

         (g) The parties agree that, subject to the requirements of the Federal
Food, Drug and Cosmetic Act, as amended from time to time, and all applicable
regulations thereunder (the "FD&C ACT") and any required approval of the United
States Food and Drug Administration (the "FDA"), the name of Pfizer or Pfizer's
Affiliate shall not appear on any Promotional Materials used or distributed in
the Territory under this Agreement.

         (h) Distributor shall not conduct any clinical or non-clinical studies
involving the Product or sponsor any publications concerning the Product without
the prior written approval of Pfizer, which shall not be unreasonably withheld.

         (i) Within two months following the execution of this Agreement, Pfizer
shall provide Distributor with access to appropriate personnel experienced with
the marketing of doxazosin mesylate in order to transfer to Distributor
marketing and reasonably related information that would be beneficial to
Distributor's promotion of the Product, in such place as mutually agreed.
Notwithstanding the foregoing, Pfizer shall not be required to provide such
representatives for a total of more than [xxxx]* person hours during such
period.

         SECTION 7.04. LABELING. The parties agree that, subject to the
requirements of the FD&C Act and any required approval of the FDA, the name of
Pfizer or Pfizer's Affiliate, on the one hand, and the name of Distributor, on
the other hand, shall be given similar exposure and prominence on all created or
manufactured Product package inserts and packaging used or distributed in the
Territory under this Agreement; PROVIDED that if only one name is permitted by
applicable Laws, it shall be the name of Pfizer or Pfizer's Affiliate. Pfizer
shall provide Distributor with a copy of all labeling content changes Pfizer has
made to the Product sold in the Territory no later than ten (10) days after any
such change is introduced to the market.

* Filed under application for confidential treatment.

                                       13
<PAGE>

                                  ARTICLE VIII
                                    TRAINING

         SECTION 8.01. TRAINING PROGRAM AND MATERIALS. Distributor shall be
responsible for the training of the Distributor's sales representatives and for
developing training materials for use in connection therewith. Distributor shall
bear all of the costs and expenses of implementing and producing its training
program and materials. Distributor's training programs for its sales
representatives will include training to comply with all applicable Laws.

                                   ARTICLE IX
                               REGULATORY MATTERS

         SECTION 9.01. REGULATORY AND LEGAL MATTERS.

         (a) Except as otherwise provided in this Section 9.01, Pfizer and its
Affiliates shall have the sole authority and responsibility to obtain and
maintain any FDA or other Governmental or Regulatory Authority approvals with
respect to the Product and Pfizer and/or its Affiliates shall own all such
approvals. Pfizer shall provide Distributor with copies of all final submissions
that are intended to change or modify the packaging, label or labeling for, or
the indications of, the Product. Except as provided in this Section 9.01,
Distributor shall not file any document with the FDA or any other Governmental
or Regulatory Authority relating to the Product, and will not take any action in
respect of any complaint, communication or report, in each case without Pfizer's
prior consent.

         (b) In the event the FDA requires that additional studies (clinical or
non-clinical), or additional pharmacokinetic or manufacturing data be provided
as a condition to approval or as a requirement following approval, Pfizer agrees
that it shall use its Commercially Reasonable Efforts to undertake such studies
at its expense.

         (c) Subject to SECTION 9.03(B) below, in the event Distributor desires
to file for additional indications or a change in label with the FDA following
NDA Approval, the parties shall meet in good faith for the purpose of coming to
a mutually agreeable approach to such filings.

         SECTION 9.02. COMMUNICATION WITH REGULATORY AUTHORITIES. Except in
relation to activities relating to the FDA's Division of Drug Marketing,
Advertising and Communications ("DDMAC") pursuant to SECTION 9.03(B) below,
Distributor shall not, without the consent of Pfizer which shall not be
unreasonably withheld or delayed or unless so required by Law (and then only
pursuant to the terms of this SECTION 9.02), correspond or communicate with the
FDA or with any other Governmental or Regulatory Authority (including Adverse
Drug Experience Reports and Serious Adverse Drug Experience Reports to the FDA
and/or other Governmental or Regulatory Authorities), whether within the
Territory or otherwise, concerning the Product or doxazosin mesylate generally
or otherwise take any action concerning any authorization or permission under
which the Product is sold or any application for the same. Furthermore,
Distributor shall, immediately upon receipt of any communication from the FDA or
from any other Governmental or Regulatory Authority relating to the Product or
doxazosin mesylate generally, forward a copy or description of the same to
Pfizer and respond to all inquiries by Pfizer relating thereto. If Distributor
is advised by its counsel that it must communicate with the FDA or with any
other Governmental or Regulatory Authority, then Distributor shall so advise

* Filed under application for confidential treatment.

                                       14
<PAGE>

Pfizer immediately and, unless prohibited by Law, provide Pfizer in advance with
a copy of any proposed written communication with the FDA or any other
Governmental or Regulatory Authority, and shall comply with any and all
reasonable directions of Pfizer concerning any meeting or written or oral
communication with the FDA or any other Governmental or Regulatory Authority.

         SECTION 9.03. LABELING AND PROMOTIONAL MATERIALS.

         (a) Pfizer and its Affiliates shall have the sole authority and
responsibility to seek and/or obtain any necessary FDA approvals of any label,
labeling, package inserts and packaging used in connection with the Product, and
for determining whether the same requires FDA approval.

         (b) Following NDA Approval, Distributor shall be solely responsible for
submission of all Promotional Materials as required by Law to DDMAC, including,
but not limited to, submission of each Form 2253 to the FDA. In addition,
Distributor agrees to seek pre-clearance from DDMAC with respect to all
Promotional Materials to be used on launch of the Product. Distributor will be
the designated recipient of all DDMAC correspondence, and agrees to be solely
responsible for responding to, and complying with, all FDA inquiries, Notices of
Violation, Warning Letters and other actions of FDA related to promotional
activities. In addition, Distributor will immediately notify Pfizer of any
Proceedings (threatened or pending), involving potential or actual violations of
Law by Distributor related to the Product. Except with respect to the Form 2253,
Distributor agrees that it will promptly provide to Pfizer copies of all
submissions to and correspondence to and from the FDA and any Proceedings
related to the Product pursuant to this Section, and Pfizer shall have the
right, but not the obligation, to comment on such submissions and
correspondence, and Distributor shall make such changes to any such
communications and submissions to the FDA and take such actions in respect
thereof as may be reasonably requested by Pfizer.

         (c) Following execution of this Agreement, Pfizer shall continue to own
the NDA, and will use its Commercially Reasonable Efforts to obtain NDA
Approval. Pfizer may file, but shall not be required to file, any additional New
Drug Applications or supplemental New Drug Applications with respect to the
Product. Pfizer agrees that it will provide to Distributor copies of
correspondence to and from the FDA related to the Product, except to the extent
such correspondence relates to any proprietary manufacturing data.

         SECTION 9.04. COMPLAINTS. Distributor shall refer any complaints which
it receives concerning the Product or doxazosin mesylate in general to Pfizer
within five (5) business days after Distributor's receipt of the same; PROVIDED
that all complaints concerning suspected or actual Product tampering, damage,
contamination or mix-up (E.G., wrong ingredients or incorrect labeling) shall be
delivered to Pfizer within one (1) business day of Distributor's receipt of the
same. Distributor shall not take any other action in respect of any such
complaint without Pfizer's consent, unless otherwise required by Law.

* Filed under application for confidential treatment.

                                       15
<PAGE>

         SECTION 9.05. REGULATORY INFORMATION. Subject to the terms of SECTION
9.02 above, each party agrees to provide the other party with all reasonable
assistance and take all actions reasonably requested by the other party that are
necessary or desirable to enable the other party to comply with any Law under
the FD&C Act applicable to the Product or doxazosin mesylate in general,
including, but not limited to, Pfizer meeting its reporting and other
obligations to: (i) maintain and update any New Drug Applications for the
Product; and (ii) report Adverse Drug Experience Reports and Serious Adverse
Drug Experience Reports to the FDA and/or other Governmental or Regulatory
Authorities. Such assistance and actions shall include, among other things,
keeping the other party informed, commencing within two (2) business days of
notification of any action by, or notification or other information which it
receives (directly or indirectly) from, the FDA or any other Governmental or
Regulatory Authority which (a) raises any material concerns regarding the safety
or efficacy of the Product, (b) indicates or suggests a potential material
liability for either party to third parties arising in connection with the
Product or (c) is reasonably likely to lead to field alert report, recall or
market withdrawal of the Product; PROVIDED that neither party shall be obliged
to disclose information in breach of any contractual restriction.

         SECTION 9.06. ADVERSE DRUG EXPERIENCE REPORTS.

         (a) Pfizer shall have sole responsibility for evaluation of, and, as
required by the FD&C Act and FDA regulations, for reporting of adverse drug
experiences to, the FDA. In order to fulfill this obligation, Distributor shall
notify Pfizer of all Adverse Drug Experience reports as defined in 21 C.F.R.
Section 314.80(a), within two (2) business days after such report becomes known
to Distributor.

         (b) Subject to SECTION 9.02 above, (i) Distributor shall not disclose
any information concerning Adverse Drug Experience Reports or Serious Adverse
Drug Experience Reports to any Person or Governmental or Regulatory Authority
without Pfizer's prior consent and (ii) Pfizer and its Affiliates shall have the
sole discretion to determine whether any complaint, Adverse Drug Experience
Report or Serious Adverse Drug Experience Report must be reported to the FDA or
any other Governmental or Regulatory Authority or any other Person.

         (c) Within ten (10) business days after submission, Pfizer shall
provide Distributor with copies of all fifteen (15) day "Alert Reports" relating
to the Product and submitted to the FDA in accordance with 21 C.F.R.
314.80(c)(1). Within ten (ten) business days after submission, Pfizer shall
provide Distributor with copies of all periodic adverse drug experience reports
relating to the Product and submitted in accordance with 21 C.F.R. 314.80(c)(2).

         (d) Distributor will train its field force to handle Adverse Drug
Experience Reports and Serious Adverse Drug Experience Reports in a manner
consistent with Pfizer's practices (including, but not limited to, instruction
in using Pfizer's toll-free number for such reports).

* Filed under application for confidential treatment.

                                       16
<PAGE>

         (e) Within sixty (60) days from execution of this Agreement,
Distributor and Pfizer shall enter into such other agreements as are reasonably
necessary to ensure that satisfactory systems and procedures are in place to
effect the effective exchange of safety and other medical information between
the two parties as necessary to fulfill all applicable legal and regulatory
requirements.

         SECTION 9.07. RECALLS OR OTHER CORRECTIVE ACTION. Pfizer and its
Affiliates shall have the sole authority and responsibility to make all
decisions with respect to any recall, market withdrawal or any other corrective
action related to the Product. Pfizer shall promptly notify Distributor of any
such recall, mandatory withdrawal or other corrective action regarding the
Product in the Territory. If a corrective action is due to Pfizer's negligence,
willful misconduct or breach of this Agreement, Pfizer shall reimburse
Distributor for the Per System Fee paid by Distributor pursuant to SECTION 5.03
hereof for any orders of the Product subject to such corrective action (other
than orders that have been resold by, and not returned to, Distributor), all of
the reasonable costs and expenses actually incurred by Distributor in connection
with such corrective action, including, but not limited to, costs of retrieving
Product already delivered to customers, costs and expenses Distributor is
required to pay for notification, shipping and handling charges, and such other
costs as may be reasonably related to the corrective action. If a corrective
action is due to Distributor's negligence, willful misconduct or breach of this
Agreement, Distributor shall remain responsible for the Per System Fee paid by
Distributor pursuant to SECTION 5.03 hereof for any orders of the Product
subject to such corrective action and shall reimburse Pfizer for all the
reasonable costs and expenses described above actually incurred by Pfizer in
connection with such corrective action, including administration of the recall
and such other actual costs as may be reasonably related to the corrective
action. If a corrective action results from a cause other than the negligence,
willful misconduct or breach of this Agreement of or by Distributor or Pfizer,
the parties hereto shall share equally, all of the costs of the corrective
action, including the Per System Fee paid by Distributor pursuant to SECTION
5.03 hereof for any orders of the Product subject to such corrective action
(other than orders that have been resold by, and not returned to, Distributor).
Prior to any reimbursements pursuant to this Section, the party claiming any
reimbursement shall provide the other party with reasonably acceptable
documentation of all reimbursable costs and expenses. Neither party will be
liable to the other for Indirect Losses in connection with any corrective action
undertaken pursuant to this Section.

         SECTION 9.08. PRODUCT TESTING/INSPECTION.

         (a) Pfizer shall perform quality assurance testing with respect to the
Products sold hereunder, including stability testing, so that the Products
conform with the Specifications. Pfizer shall provide to Distributor a
certificate for the Product describing the Product, product number, lot number
and expiration date, the physical, chemical, biological or other testing results
and specifications relating to the Product and certifying that the Product meets
the Specifications to Distributor in the form of a Certificate of Analysis
(hereinafter "COA"). Pfizer will also provide Distributor with Material Safety
Data Sheets (hereinafter "MSDS") as required for the Products, and updates of
same as necessary.

         (b) Distributor shall have a period of [xxxx]* from the later of (a)
the date of Distributor's receipt of the Products in accordance with Article III
hereof, or (b) the date of Distributor's receipt of the COA's applicable to such
Product, to inspect any shipment of a Product to determine whether such shipment
conforms to the Specifications. If Distributor determines that a Product does
not conform to the Specifications, it shall notify Pfizer, immediately, if
possible, but no later than [xxxx]* after determining a Product does not conform
to the Specifications. Distributor's failure to notify Pfizer within the

* Filed under application for confidential treatment.

                                       17
<PAGE>

stipulated period will be deemed, for purposes of this Agreement, as
Distributor's acceptance of such shipment and shall constitute a waiver of any
claims Distributor may have against Pfizer with respect to such shipment
subject, however, to Distributor's right to reject such Product for latent
defects discovered by Distributor or Distributor's customer(s) after such
stipulated period has expired. If Pfizer agrees that a Product does not conform
to the Specifications, Distributor shall return the non-conforming Product to
Pfizer, at a location designated by Pfizer and at Pfizer's expense. Pfizer, at
no expense to Distributor, shall use Commercially Reasonable Efforts to replace
any non-conforming Product within the shortest possible time.

         (c) In the event Pfizer does not agree with Distributor's determination
that a Product fails to meet Specifications, the Parties shall, in good faith,
attempt to resolve such dispute. In the event the Parties cannot resolve said
dispute among themselves they may submit the matter to an independent third
party testing laboratory agreeable to both Distributor and Pfizer for a binding
opinion. The expenses of obtaining the binding opinion shall be equally shared
by Distributor and Pfizer. In the event that the Parties do not agree to submit
the dispute to a testing laboratory, the Parties shall remain free to pursue any
legal, equitable or administrative remedies to which they may be entitled.

         (d) Distributor will permit Pfizer's personnel, upon reasonable notice,
to visit at reasonable intervals, and for reasonable durations during regular
business hours, any facility used by Distributor for the storage and
distribution of the Product and will allow such personnel to review and make
copies of any relevant records in connection therewith.

                                   ARTICLE X
                    REPRESENTATIONS, COVENANTS AND WARRANTIES

         SECTION 10.01. PFIZER REPRESENTATIONS AND WARRANTIES. Pfizer hereby
represents and warrants to Distributor as follows:

         (a) The execution, delivery and performance by Pfizer of this Agreement
and the consummation of the transactions contemplated hereby are within Pfizer's
corporate powers and have been duly authorized by all necessary corporate action
on the part of Pfizer. This Agreement constitutes a legal, valid and binding
obligation of Pfizer, enforceable against Pfizer in accordance with its terms;

         (b) As of the date hereof, the execution, delivery and performance of
this Agreement by Pfizer will not violate in any material respect any Laws or
any order of any Governmental or Regulatory Authority;

         (c) As of the date hereof, none of the execution, delivery or
performance of this Agreement by Pfizer requires Pfizer to obtain any permits,
authorizations or consents from any Governmental or Regulatory Authority (except
for FDA approval of the Product), and such execution, delivery and performance
will not result in a material breach of or give rise to any termination of any
material agreement or contract to which Pfizer may be a party and which relates
to the Product in the Territory and, except for FDA approval of the Product,
Pfizer has, and will maintain throughout the term of this Agreement all permits,

* Filed under application for confidential treatment.

                                       18
<PAGE>

licenses, representations and all forms of governmental authorization and
approval as required by law in order for Pfizer to execute, deliver and perform
its obligations hereunder; and

         (d) Except as set forth in this SECTION 10.01, Pfizer gives no other
warranty, express or implied.

         SECTION 10.02. DISTRIBUTOR REPRESENTATIONS AND WARRANTIES. Distributor
hereby represents and warrants to Pfizer as follows:

         (a) The execution, delivery and performance by Distributor of this
Agreement and the consummation of the transactions contemplated hereby are
within Distributor's corporate powers and have been duly authorized by all
necessary corporate action on the part of Distributor. This Agreement
constitutes a legal, valid and binding obligation of Distributor, enforceable
against Distributor in accordance with its terms. Distributor is properly
registered, licensed and qualified, and has all requisite power and authority
under its organizational documents and in accordance with the Laws of the
Territory to act as Pfizer's distributor, and to conduct its business and
perform its obligations hereunder and, during the Term of this Agreement and any
extensions thereof, it shall take all action as may be required and necessary to
obtain and keep current any governmental licenses, permits, registrations and
approvals that are necessary or advisable for it to carry out its activities
hereunder;

         (b) As of the date hereof, the execution, delivery and performance of
this Agreement by Distributor will not violate in any material respect any Laws
or any order of any Governmental or Regulatory Authority; and

         (c) As of the date hereof, none of the execution, delivery or
performance of this Agreement by Distributor requires Distributor to obtain any
permits, authorizations or consents from any Governmental or Regulatory
Authority, and such execution, delivery and performance will not result in a
material breach of or give rise to any termination of any material agreement or
contract to which Distributor may be a party and which relates to the Product in
the Territory.

         SECTION 10.03. PFIZER COVENANTS. Pfizer covenants and agrees that:

         (a) Pfizer shall carry out, or shall cause its Affiliates to carry out,
the manufacturing of the Product and Pfizer's other obligations and activities
hereunder in all material respects in accordance with (i) the terms of this
Agreement; (ii) accepted pharmaceutical industry practices; (iii) current good
manufacturing practices set forth in Title 21 of the C.F.R. Parts 210 and 211,
as amended from time to time, and other FDA regulations and guidelines issued
under 21 C.F.R. 10.90 relating to the manufacture, processing, testing, packing
and storage of drug products regulated by the FDA; (iv) the Specifications; and
(v) all applicable Laws, including, but not limited to, those Laws regarding the
handling, storage, transportation, generation and disposal of waste and
regulated substances; and

         (b) The Product to be delivered by Pfizer or its Affiliates to
Distributor will not, at the time of shipment by or on behalf of Pfizer, in any
material respect be misbranded or adulterated under the terms of the FD&C Act.

* Filed under application for confidential treatment.

                                       19
<PAGE>

         (c)      (i)      [xxxx]*

                  (ii)     [xxxx]*

                  (iii)    [xxxx]*

         SECTION 10.04. DISTRIBUTOR COVENANT.

         (a) Distributor shall carry out the distribution, detailing, promotion
and marketing of the Product and its other obligations and activities hereunder
in all material respects in accordance with (i) the terms of this Agreement,
(ii) accepted pharmaceutical industry practices and (iii) all applicable Laws.

         (b) The Product to be Distributed by the Distributor to unaffiliated
third parties will not, at the time of such shipment, in any material respect be
misbranded or adulterated under the terms of the FD&C Act.

                                   ARTICLE XI
                              INTELLECTUAL PROPERTY

         SECTION 11.01. INTELLECTUAL PROPERTY.

         (a) The Product shall initially be promoted and sold in the Territory
under the Cardura(R)XL trademark (U.S. Trademark Registration No. 1,360,101)
owned by Pfizer (the "TRADEMARK").

         (b) Pfizer hereby grants Distributor a non-exclusive, royalty-free
license, with the right to further sublicense solely to its Affiliates, to use
the Trademark in the Territory in connection with this Agreement, including, but
not limited to, Promotional Materials, and promoting and detailing the Product.
Upon termination or expiration of this Agreement, Distributor shall discontinue
all use of the Trademark. Except for the licenses granted in this Section,
Distributor shall not have or acquire any ownership, proprietary or property
right or other interest in the Trademark, any other trademarks, its related
goodwill, nor in any patents, know-how, technical information or in any
copyright owned or otherwise held by Pfizer or any of its Affiliates and
relating to the Product.

         (c) Distributor owns the Distributor logo set forth on Exhibit D
attached hereto (the "DISTRIBUTOR LOGO"). Distributor hereby grants Pfizer and
its Affiliates a non-exclusive royalty-free license to use the Distributor Logo
in the Territory on labeling, package inserts and packaging materials for
Product, all Promotional Materials and any other materials used in connection
with the performance of this Agreement during the Term hereof. Distributor shall
have the right to approve the design, color and specifications of the
Distributor Logo itself on all materials used in connection with this Agreement.
After the expiration or termination of this Agreement, Pfizer shall not create
or produce any materials bearing the Distributor Logo. Except as provided in
this Section, Pfizer shall have no rights under this Agreement in or to the
Distributor Logo or the goodwill pertaining thereto and agrees that upon

* Filed under application for confidential treatment.

                                       20
<PAGE>

termination or expiration of this Agreement, except for the period specified
above, it shall discontinue all use of the Distributor Logo. All uses of the
Distributor Logo inure solely to Distributor's benefit.

         SECTION 11.02. PATENT AND TRADEMARK INFRINGEMENT.

         (a) Each party shall promptly notify the other party upon its becoming
aware of (i) any infringement in the Territory by any Person of any patent, the
Trademark, the Distributor Logo or any copyrights relating to the Product and
(ii) any patent or trademark infringement action brought against such party or
any of its Affiliates with respect to the Product. Except for trademark
infringement of the Distributor Logo, and subject to the rights of ALZA
Corporation ("ALZA") pursuant to the License Agreement between ALZA and Pfizer,
dated October 8, 1987. Pfizer shall have the sole and absolute discretion
whether or not to bring suit to enjoin, prohibit, or retard any third party
infringement; PROVIDED that if Pfizer becomes aware that a third party has
either filed a certification under Section 505(b)(2)(A)(iv) of the FD&C Act for
the Product or an ANDA with the FDA for the Product, subject to the rights of
ALZA, Pfizer shall use reasonable efforts to consult with Distributor prior to
deciding (in Pfizer's sole and absolute discretion) whether to exercise its
rights provided under Law, including the FD&C Act. Pfizer shall be solely
responsible for all out-of-pocket expenses incurred in connection with such
infringement suits and shall have the sole right to any recoveries made
thereunder, subject to the rights of ALZA. Distributor shall, at Pfizer's
request and expense, cooperate fully in such suits or actions. Distributor shall
have the sole discretion whether or not to bring suit to enjoin, prohibit, or
retard any third party infringement of the Distributor Logo in connection with
the Product. Distributor shall be solely responsible for all out-of-pocket
expenses incurred in connection with such infringement suits and shall have sole
rights to any recoveries made thereunder. Pfizer shall, at Distributor's request
and expense, cooperate fully in such suits or actions.

         (b) Each party shall promptly notify the other party upon receipt of
any communications from Governmental or Regulatory Authorities in the Territory
with respect to the Trademark or any patents or copyrights relating to the
Product.

                                  ARTICLE XII
                       INFORMATION CONCERNING THE PRODUCT

         SECTION 12.01. OWNERSHIP. Distributor shall not represent to any third
party that it has any proprietary or property right or other interest in the
Product, doxazosin mesylate or in the Trademark or any patents or copyrights
relating to the Product, except for such rights granted to Distributor under
this Agreement.

         SECTION 12.02. MEDICAL INQUIRIES. Distributor shall have sole
responsibility for responding to all medical questions or inquiries from members
of the medical and paramedical professions and consumers relating to the
Product. However, Distributor shall comply with the directions and policies
which Pfizer may reasonably formulate concerning responses to be made to medical
questions or inquiries from members of the medical and paramedical professions
and consumers regarding the Product, including, but not limited to, forms of
response letters, and shall, if so requested by Pfizer, provide Pfizer with
details of inquiries received and responses given.

* Filed under application for confidential treatment.

                                       21
<PAGE>

                                  ARTICLE XIII
                              TERM AND TERMINATION

         SECTION 13.01. TERM. (a) The term of this Agreement (herein referred to
as the "TERM") shall commence on the date first set forth above and shall
continue for an initial period of [xxxx]* from the date of NDA Approval.
Thereafter, this Agreement may be renewed on a year to year basis upon mutual
written consent of both parties. Pfizer shall give Andrx written notice no later
than [xxxx]* prior to the expiration of the Term (or any renewal period) as to
its intent to renew or terminate this Agreement; provided, however, that if no
such notice is given, this Agreement shall not renew and shall terminate at its
then scheduled termination date. Distributor shall give Pfizer written notice no
later than [xxxx]* following Pfizer's renewal notice whether it agrees to extend
the Term.

         (b) [xxxx]*

         (c) At such time that Pfizer fails to give notice to renew or the
parties otherwise do not agree to renew the Term, at such time Distributor's
obligation to maintain the Minimum Inventory pursuant to Section 5.04 shall be
of no further force and effect. Moreover, following the termination date, at
Pfizer's option, Distributor shall be permitted to either continue to sell off
its remaining inventory to third parties or be authorized to return said
inventory to Pfizer at the Per System Fee.

         SECTION 13.02. TERMINATION BY PFIZER. Notwithstanding anything
contained herein, Pfizer may immediately terminate this Agreement prior to the
expiration of the Term or any renewal thereof, by giving written notice given to
Distributor upon the occurrence of one or more of the following events, which
for all purposes, shall be deemed to be and shall be treated as just cause for
such termination:

         (a) In the event that:

                  (i) NDA Approval is not obtained prior to December 31, 2004;

                  (ii) FDA approval of the NDA is received with manufacturing
         specifications which differ from Pfizer's response to the FDA regarding
         the NDA and Pfizer provides notice to Distributor that it will not
         manufacture the Product with such specifications;

         (b) In the event that regulatory authorities in the United States of
America withdraw marketing approval of the Product;

         (c) In the event that Distributor fails to purchase the minimum
quantities of Product in any of the [xxxx]* Contract Years;

         (d) In the event that with respect to its promotional, educational or
detailing activities of the Product, the Distributor (i) receives any Warning
Letter from the FDA and fails to use Commercially Reasonable Efforts to remedy
same and satisfactorily resolve the matters raised in such letter within a

* Filed under application for confidential treatment.

                                       22
<PAGE>

reasonable time, or is subject to a criminal indictment or is otherwise formally
accused by any Governmental or Regulatory Authority with a violation of Law or
(ii) is otherwise engaged in a pattern of conduct resulting in multiple Notices
of Violation from the FDA or inquiries from the FDA or other Governmental or
Regulatory Authorities.

         (e) In the event manufacture, distribution or sale of the Product in
the Territory contravenes any Law; provided that it shall not terminate in the
event manufacture, distribution or sale can be brought into compliance with Law
within a reasonable time;

         (f) In the event of a material breach by Distributor of the terms and
conditions hereof and a failure to cure such breach within thirty (30) days of
receipt of written notice by Distributor;

         (g) In the event of bankruptcy, receivership, liquidation or insolvency
of Distributor or in the event that any valid similar actions or proceedings are
instituted by, on behalf of or against Distributor;

         (h) Upon any assignment or attempted assignment (whether by contract,
operation of Law or otherwise) by Distributor of any interest in this Agreement
without Pfizer's prior written consent;

         (i) Upon the unauthorized solicitation of sales of the Product outside
of the Territory by Distributor or the unauthorized sales of the Product outside
the Territory by Distributor, other than isolated situations involving sales of
non-material quantities of Product; and

         (j) In the event that it becomes physically or legally impossible or
commercially impracticable for either party to perform its obligations by virtue
of Force Majeure pursuant to SECTION 16.05 hereof.

It is agreed that Distributor shall immediately advise Pfizer in writing of the
occurrence of any event specified in this Article, provided that the giving of
such notice shall not be a condition precedent to the exercise of Pfizer of its
rights hereunder.

         SECTION 13.03. TERMINATION BY DISTRIBUTOR. Notwithstanding anything
contained herein, Distributor may terminate this Agreement prior to the
expiration of the Term or any renewal thereof, by giving [xxxx]* written notice
to Pfizer upon the occurrence of one or more of the following events (provided,
however, that upon the occurrence of the event in SECTION 13.03(A), Distributor
may immediately terminate this Agreement), which for all purposes, shall be
deemed to be and shall be treated as just cause for such termination:

         (a) In the event NDA Approval is not obtained prior to [xxxx]*, or if
the NDA Approval does not meet all or substantially all of the criteria for each
claim set forth on Attachment I hereto;

         (b) In the event that regulatory authorities in the United States of
America withdraw marketing approval of the Product;

* Filed under application for confidential treatment.

                                       23
<PAGE>

         (c) In the event manufacture, distribution or sale of the Product
contravenes any Law; provided that it shall not terminate in the event
manufacture, distribution or sale can be brought into compliance with Law within
a reasonable time;

         (d) Except as provided in this Agreement (including, without
limitation, in Section 3.05(f) hereof), in the event of a material breach by
Pfizer of the terms and conditions hereof and a failure to cure such breach
within thirty (30) days of receipt of written notice by Pfizer; and

         (e) In the event that it becomes physically or legally impossible or
commercially impracticable for either party to perform its obligation by virtue
of Force Majeure pursuant to and under the terms described in SECTION 16.05
hereof.

It is agreed that Pfizer will immediately advise Distributor in writing of the
occurrence of any event specified in this Article, provided that the giving of
such notice shall not be a condition precedent to the exercise of Distributor of
its rights hereunder.

         SECTION 13.04. EFFECTS OF TERMINATION.

         (a) Except as otherwise provided herein, any termination of this
Agreement shall not release either party from any obligation to pay to the other
party any sums due under ARTICLE V in connection with activities completed on or
before the date of such termination, but no further sums shall be payable under
ARTICLE V; PROVIDED that such termination shall be without prejudice to any
remedies which either party may then have hereunder or at Law.

         (b) The provisions of SECTION 14.01 and ARTICLE XV, SECTION 16.01 and
this SECTION 13.04 shall survive the expiration or termination hereof
indefinitely. The obligations of the parties set forth in SECTION 9.02, SECTION
9.04, SECTION 9.05 and SECTION 9.03(A) shall survive the expiration or
termination hereof for the shelf life of the items containing the Distributor
Logo in accordance with SECTION 11.01(C). The provisions of ARTICLE V shall
survive the termination hereof in accordance with their terms.

         (c) Subject to the terms of SECTION 14.01, within thirty (30) days
after the expiration or termination of this Agreement, (i) Distributor shall
return to Pfizer all Promotional Materials, Marketing Plans, reports and all
other tangible Confidential Information provided to, or based upon Confidential
Information provided to, Distributor by or on behalf of Pfizer and (ii) Pfizer
shall return to Distributor all tangible Confidential Information provided to,
or based upon Confidential Information provided to, Pfizer by or on behalf of
Distributor.

                                  ARTICLE XIV
                       CONFIDENTIALITY AND PRESS RELEASES

         SECTION 14.01. CONFIDENTIALITY. For a period of [xxxx]* following
termination of this Agreement, each party shall hold in confidence and use only
in furtherance of its rights and obligations under this Agreement all
Confidential Information that it acquires from the other party pursuant to this
Agreement, unless (i) the disclosing party consents to the receiving party's
disclosure or use or (ii) disclosure of the disclosing party's Confidential
Information by the receiving party is required by order of any Governmental or
Regulatory Authority, in which event the receiving party will notify the

* Filed under application for confidential treatment.

                                       24
<PAGE>

disclosing party of that order as soon as practicable, shall use reasonable
efforts (at the disclosing party's expense) to obtain a protective order
covering the Confidential Information and shall disclose only such Confidential
Information that its legal counsel determines is legally required. Each party
shall make Confidential Information that it acquires from the other party
pursuant to this Agreement available only to those of its Affiliates, directors,
officers, employees, consultants, advisors or representatives who need to have
access thereto for the purposes of this Agreement and who are bound by an
obligation of confidentiality consistent with the provisions herein.

         SECTION 14.02. PRESS RELEASES. Except as required by any Governmental
or Regulatory Authority, neither party shall make any press release or other
public announcement or other disclosure to third parties (other than its
advisors) relating to the Agreement or the transactions described herein without
the prior written consent of the other party.

                                   ARTICLE XV
                                 INDEMNIFICATION

         SECTION 15.01. INDEMNIFICATION BY DISTRIBUTOR. Distributor agrees to
indemnify, protect, defend and hold Pfizer and its directors, officers,
employees and agents harmless from and against any Losses that they may incur at
any time arising out of (i) Distributor's breach of this Agreement or of any
warranty made by Distributor to Pfizer in this Agreement or (ii) Distributor's
promotional, marketing, advertising, detailing and educational activities and
from its storage, handling and distribution of the Product supplied to it by
Pfizer.

         SECTION 15.02. INDEMNIFICATION BY PFIZER. Pfizer agrees to indemnify,
protect, defend and hold Distributor and its directors, officers, employees and
agents harmless from and against any Losses that they may incur at any time
arising out of (i) Pfizer's breach of this Agreement or of any warranty made by
Pfizer to Distributor in this Agreement or (ii) Pfizer's supply of damaged or
defective Product that does not meet the Specifications authorized under the NDA
Approval, provided, however, that Distributor shall not be indemnified under
this Section (i) for any individual third party claims involving Losses of less
than [xxxx]* and (ii) unless and until the aggregate amount of all third party
claims involving Losses of [xxxx]* or more exceeds [xxxx]*, in which event
Pfizer shall be liable only for such indemnified aggregate Losses in excess of
[xxxx]*. In addition, Pfizer shall not be liable to, or be required to
indemnify, Distributor under this Section for an aggregate amount of Losses
exceeding the total amount of payments made by Distributor to Pfizer pursuant to
ARTICLE V of this Agreement. Except with respect to Product Liability Claims,
Distributor acknowledges and agrees that the provisions of this Section 15.02
and other applicable provisions of this ARTICLE XV shall be the sole and
exclusive remedy of Distributor in respect of any third party claim made against
Distributor.

         SECTION 15.03. JOINT INDEMNIFICATION. SECTION 15.01 and SECTION 15.02
notwithstanding, if the Losses arising from any Product Liability Claim are a
result of Pfizer's negligence, willful misconduct or a breach of this Agreement,
Pfizer shall bear responsibility for all the Losses arising under such Product
Liability Claim. If the Losses arising from any Product Liability Claim are a
result of Distributor's negligence, willful misconduct or a breach of this
Agreement, Distributor shall bear responsibility for all the Losses arising
under such Product Liability Claim. If the Losses arising from any Product
Liability Claim are not a result of either Party's negligence, willful
misconduct or a breach of this Agreement, the Parties shall share the Losses
equally. Upon receipt of any such Product Liability Claim, each party promptly

* Filed under application for confidential treatment.

                                       25
<PAGE>

will notify the other party in writing of such Product Liability Claim. Pfizer
shall have the right to defend against and control the defense and settlement of
such Product Liability Claim, provided that (a) Pfizer (i) shall assume the
conduct of such defense within thirty (30) days of notice of such claim or suit
and (ii) shall not compromise or settle such claim or suit without the written
approval of Distributor to the extent such claim or suit involves equitable or
non-monetary relief legally binding upon Distributor or forces Distributor to
take any action (but in all other instances shall consult with Distributor prior
to settlement, if practical), and (b) Distributor shall have the right to
participate in the defense of such claim or suit at its own expense. Distributor
shall not compromise or settle such claim or suit or make any admissions
concerning such claim or suit (unless required by applicable Law) without the
prior written approval of Pfizer.

         SECTION 15.04. PROCEDURES. The party seeking indemnification under this
ARTICLE XV (the "INDEMNIFIED PARTY") agrees to give prompt notice to the party
against whom indemnity is sought (the "INDEMNIFYING PARTY") of the assertion or
commencement of any Proceeding in respect of which indemnity may be sought under
such Section and will provide the Indemnifying Party such information with
respect thereto that the Indemnifying Party may reasonably request. The failure
to give such notice shall relieve the Indemnifying Party of any liability
hereunder only to the extent that the Indemnifying Party has suffered actual
prejudice thereby. Except as provided in SECTION 15.03 above, the Indemnifying
Party shall have the right to participate in and control the defense of any such
action, suit or proceeding at its own expense. The Indemnified Party shall, if
requested by the Indemnifying Party, cooperate in all reasonable respects in
such defense. The Indemnified Party shall be entitled at its own expense to
participate in such defense and to employ separate counsel for such purpose. The
Indemnifying Party shall not be liable under this ARTICLE XV for any settlement
effected without its consent of any Proceeding in respect of which indemnity may
be sought hereunder. No party to this Agreement shall enter into any compromise
or settlement which commits the other party to take, or to forbear to take, any
action without the other party's prior written consent.

         SECTION 15.05. INSURANCE PROCEEDS; TAXES. Any indemnification hereunder
shall be made net of any insurance proceeds recovered or recoverable by the
Indemnified Party from third parties and net of any net tax benefits
attributable to such Losses. If, following the payment to the Indemnified Party
of any amount under this ARTICLE XV, such Indemnified Party recovers any
insurance proceeds in respect of the claim for which such indemnification
payment was made, the Indemnified Party shall promptly pay an amount equal to
the amount of such proceeds (but not exceeding the amount of such
indemnification payment) to the Indemnifying Party.

         SECTION 15.06. LIMITATION ON LIABILITY. Notwithstanding anything to the
contrary contained herein, indemnification hereunder only shall include
liability for any Indirect Losses to the extent the Indemnified Party pays such
amount to a third party in respect of a claim of such third party. Except as
expressly provided in the preceding sentence, no party to this Agreement shall
be liable to or otherwise responsible to any other party hereto or, as
applicable, Pfizer or Distributor for Indirect Losses that arise out of or
relate to this Agreement or the performance or breach hereof.

* Filed under application for confidential treatment.

                                       26
<PAGE>

                                  ARTICLE XVI
                                  MISCELLANEOUS

         SECTION 16.01. CHOICE OF LAW; JURISDICTION. This Agreement shall be
governed by and construed exclusively in accordance with the law of the State of
New York, without regard to the conflicts of law rules of such state. With
respect to any Proceeding relating to this Agreement, each party hereto
irrevocably (i) agrees and consents to be subject to the exclusive jurisdiction
of the United States District Court for the Southern District of New York or any
New York State court sitting in New York City and (ii) waives any objection
which it may have at any time to the laying of venue of any Proceeding brought
in any such court, waives any claim that such Proceeding has been brought in an
inconvenient forum and further waives the right to object, with respect to such
Proceeding, that such court does not have any jurisdiction over such party.

         SECTION 16.02. INDEPENDENT CONTRACTOR. It is expressly agreed that
Distributor is an independent contractor and has no authority to act for or on
behalf of Pfizer or Pfizer's Affiliates or to bind Pfizer or its Affiliates to
any contract or in any other manner commit Pfizer or its Affiliates or make
warranties for Pfizer or its Affiliates in any way without the prior express
written approval of Pfizer, except as may be otherwise provided herein. Further,
nothing contained herein shall constitute an agency, a partnership or a joint
venture between the parties hereto.

         SECTION 16.03. NOTICES. All notices or other communications hereunder
shall be deemed sufficient if given in writing, mailed registered mail (return
receipt requested), postage paid, or by facsimile (confirmed by such registered
mail) or by courier addressed to the appropriate party at the address set forth
below, or at such other place as such party may designate in writing to the
other party.

* Filed under application for confidential treatment.

                                       27
<PAGE>

         If to Pfizer:

         PFIZER INC.
         235 East 42nd Street
         New York, New York 10017
         Attn:  Jeffrey Kindler, Esq.
         Senior Vice President and General Counsel
         Telephone No. (212) 733-4935
         Facsimile No. (212) 808-8924

         If to Distributor:

         ANDRX CORPORATION
         4955 Orange Drive
         Davie, Florida 33314
         Attn:  Scott Lodin, Esq.
                Executive Vice President and General Counsel

         All such notices shall be effective five (5) days following the date of
mailing.

         SECTION 16.04. INTENTIONALLY OMITTED

         SECTION 16.05. FORCE MAJEURE. No party shall be liable for delay in
performing or failure to perform obligations hereunder (in no event to include
the obligation to pay money), and no party shall be deemed in breach of its
obligations hereunder (in no event to include the obligation to pay money), if
such failure or delay is due to any event of Force Majeure. If such failure or
delay exceeds ninety (90) consecutive days and would otherwise be a material
breach of this Agreement, the party without the obligation to perform may
terminate this Agreement upon fifteen (15) days' prior notice, provided that at
the time of serving notice the event of Force Majeure persists.

         SECTION 16.06. SEVERABILITY. Whenever possible, each provision of this
Agreement shall be interpreted in such a manner as to be effective and valid
under applicable Law, but if any provision of this Agreement is held to be
prohibited by or invalid under applicable Law, such provision shall be
ineffective only to the extent of such prohibition or invalidity, without
invalidating the remainder of this Agreement.

         SECTION 16.07. HEADINGS. The headings used in this Agreement have been
inserted for convenience of reference only and do not define or limit the
provisions hereof.

         SECTION 16.08. AMENDMENTS AND WAIVERS.

                  (a) Any provision of this Agreement may be amended or waived
         if, but only if, such amendment or waiver is in writing and is signed,
         in the case of an amendment, by each party to this Agreement, or in the

* Filed under application for confidential treatment.

                                       28
<PAGE>
case of a waiver, by the party against whom the waiver is to be effective.

                  (b) No failure or delay by any party in exercising any right,
power or privilege hereunder shall operate as a waiver thereof nor shall any
single or partial exercise thereof preclude any other or further exercise
thereof or the exercise of any other right, power or privilege. Except to the
extent specifically provided herein, the rights and remedies herein provided
shall be cumulative and not exclusive of any rights or remedies provided by Law.

         SECTION 16.09. ENTIRE AGREEMENT. This Agreement (including the Exhibits
and Schedules attached hereto) constitutes the entire agreement between the
parties hereto with respect to the subject matter hereof and supersedes all
previous agreements, whether written or oral, with respect to such subject
matter.

         SECTION 16.10. THIRD PARTY BENEFICIARIES. None of the provisions of
this Agreement shall be for the benefit of or enforceable by any third party,
including, but not limited to, any creditor of either party hereto. No such
third party shall obtain any right under any provision of this Agreement or
shall by reasons of any such provision make any claim in respect of any debt,
liability or obligation (or otherwise) against either party hereto.

                  [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

* Filed under application for confidential treatment.

                                       29
<PAGE>

         IN WITNESS WHEREOF, this Agreement has been executed by a duly
authorized officer of each party as of the date first above written.

PFIZER INC.

By:
    ------------------------------------
Name:
Title:

ANDRX CORPORATION

By:
    ------------------------------------
Name:
Title:<PAGE>

                                                                     EXHIBIT 4.1

                               CUMULUS MEDIA INC.

                           2004 EQUITY INCENTIVE PLAN

1.          PURPOSE. The purpose of the 2004 Equity Incentive Plan is to attract
      and retain officers, key employees, non-employee directors and consultants
      for Cumulus Media Inc., a Delaware corporation, and its Subsidiaries and
      to provide to such persons incentives and rewards for superior
      performance.

2.          DEFINITIONS. As used in this Plan,

      (a)         "Board" means the Board of Directors of the Company and, to
            the extent of any delegation by the Board to a committee (or
            subcommittee thereof) pursuant to Section 13 of this Plan, such
            committee (or subcommittee).

      (b)         "Business Combination" means a reorganization, merger or
            consolidation or sale or other disposition of all or substantially
            all of the assets of the Company.

      (c)         "Change in Control" will have the meaning provided in Section
            9 of this Plan.

      (d)         "Code" means the Internal Revenue Code of 1986, as amended
            from time to time.

      (e)         "Common Shares" means the shares of Class A common stock, par
            value $.01 per share, of the Company or any security into which such
            Common Shares may be changed by reason of any transaction or event
            of the type referred to in Section 8 of this Plan.

      (f)         "Company" means Cumulus Media Inc., a Delaware corporation.

      (g)         "Date of Grant" means the date specified by the Board on which
            a grant of Option Rights or a grant or sale of Restricted Shares or
            Deferred Shares will become effective (which date will not be
            earlier than the date on which the Board takes action with respect
            thereto).

      (h)         "Deferral Period" means the period of time during which
            Deferred Shares are subject to deferral limitations under Section 6
            of this Plan.

      (i)         "Deferred Shares" means an award made pursuant to Section 6 of
            this Plan of the right to receive Common Shares at the end of a
            specified Deferral Period.

      (j)         "Director" means a member of the Board of Directors of the
            Company.

<PAGE>

      (k)         "Evidence of Award" means an agreement, certificate,
            resolution or other type or form of writing or other evidence
            approved by the Board that sets forth the terms and conditions of
            the awards granted. An Evidence of Award may be in an electronic
            medium, may be limited to notation on the books and records of the
            Company and, with the approval of the Board, need not be signed by a
            representative of the Company or a Participant.

      (l)         "Exchange Act" means the Securities Exchange Act of 1934, as
            amended, and the rules and regulations thereunder, as such law,
            rules and regulations may be amended from time to time.

      (m)         "Incentive Stock Options" means Option Rights that are
            intended to qualify as "incentive stock options" under Section 422
            of the Code or any successor provision.

      (n)         "Market Value per Share" means, as of any particular date, (i)
            the closing sale price per Common Share as reported on the principal
            exchange on which Common Shares are then trading or if there are no
            sales on such day, on the next preceding trading day during which a
            sale occurred, or (ii) if clause (i) does not apply, the fair market
            value of the Common Shares as determined by the Board.

      (o)         "Optionee" means the optionee named in an Evidence of Award
            evidencing an outstanding Option Right.

      (p)         "Option Price" means the purchase price payable on exercise of
            an Option Right.

      (q)         "Option Right" means the right to purchase Common Shares upon
            exercise of an option granted pursuant to Section 4 of this Plan.

      (r)         "Participant" means a person who is selected by the Board to
            receive benefits under this Plan and who is at the time an officer,
            key employee, non-employee director or consultant of the Company or
            any one or more of its Subsidiaries, or who has agreed to commence
            serving in any of such capacities within 90 days of the Date of
            Grant.

      (s)         "Person" means any individual, entity or group (within the
            meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act).

      (t)         "Plan" means this Cumulus Media Inc. 2004 Equity Incentive
            Plan.

      (u)         "Restricted Shares" means Common Shares granted or sold
            pursuant to Section 5 of this Plan as to which neither the
            substantial risk of forfeiture nor the prohibition on transfers
            referred to in such Section 5 has expired.

      (v)         "Subsidiary" means a corporation, company or other entity (i)
            more than 50 percent of whose outstanding shares or securities
            (representing the right to vote for the election of directors or
            other managing authority) are, or (ii) which does

                                       2
<PAGE>

            not have outstanding shares or securities (as may be the case in a
            partnership, joint venture or unincorporated association), but more
            than 50 percent of whose ownership interest representing the right
            generally to make decisions for such other entity is, now or
            hereafter, owned or controlled, directly or indirectly, by the
            Company except that for purposes of determining whether any person
            may be a Participant for purposes of any grant of Incentive Stock
            Options, "Subsidiary" means any corporation in which at the time the
            Company owns or controls, directly or indirectly, more than 50
            percent of the total combined voting power represented by all
            classes of stock issued by such corporation.

      (w)         "Voting Power" means at any time, the combined voting power of
            the then-outstanding securities entitled to vote generally in the
            election of Directors in the case of the Company, or members of the
            board of directors or similar body in the case of another entity.

3.          SHARES AVAILABLE UNDER THE PLAN.

      (a)         Subject to adjustment as provided in Section 3(b) and Section
            8 of this Plan, the number of Common Shares that may be issued or
            transferred (i) upon the exercise of Option Rights, (ii) as
            Restricted Shares and released from substantial risks of forfeiture
            thereof, (iii) as Deferred Shares or (iv) in payment of dividend
            equivalents paid with respect to awards made under the Plan will not
            exceed in the aggregate 2,795,000. Common Shares, plus any shares
            described in Section 3(b). Such shares may be shares of original
            issuance or treasury shares or a combination of the foregoing.

      (b)         The number of shares available in Section 3(a) above will be
            adjusted to account for shares relating to awards that expire or are
            forfeited or that are transferred, surrendered or relinquished upon
            the payment of any Option Price by the transfer to the Company of
            Common Shares or upon satisfaction of any withholding amount. Upon
            payment in cash of the benefit provided by any award granted under
            this Plan, any shares that were covered by that award will again be
            available for issue or transfer hereunder.

      (c)         Notwithstanding anything in this Section 3, or elsewhere in
            this Plan, to the contrary and subject to adjustment as provided in
            Section 8 of this Plan, (i) the aggregate number of Common Shares
            actually issued or transferred by the Company upon the exercise of
            Incentive Stock Options will not exceed 1,400,000 Common Shares;
            (ii) no Participant will be granted Option Rights for more than
            500,000 Common Shares during any calendar year; and (iii) the number
            of shares issued as Restricted Shares and Deferred Shares will not
            (after taking any forfeitures into account) in the aggregate exceed
            925,000 Common Shares.

                                       3
<PAGE>

4.          OPTION RIGHTS. The Board may, from time to time and upon such terms
      and conditions as it may determine, authorize the granting to Participants
      of options to purchase Common Shares. Each such grant may utilize any or
      all of the authorizations, and will be subject to all of the requirements
      contained in the following provisions:

      (a)         Each grant will specify the number of Common Shares to which
            it pertains subject to the limitations set forth in Section 3 of
            this plan.

      (b)         Each grant will specify an Option Price per share, which may
            not be less than the Market Value per Share on the day immediately
            preceding the Date of Grant.

      (c)         Each grant will specify whether the Option Price will be
            payable (i) in cash or by check acceptable to the Company, (ii) by
            the actual or constructive transfer to the Company of Common Shares
            owned by the Optionee for at least 6 months (or other consideration
            authorized pursuant to Section 4(d)) having a value at the time of
            exercise equal to the total Option Price, or (iii) by a combination
            of such methods of payment.

      (d)         The Board may determine, at or after the Date of Grant, that
            payment of the Option Price of any Option Right (other than an
            Incentive Stock Option) may also be made in whole or in part in the
            form of Restricted Shares or Deferred Shares. Unless otherwise
            determined by the Board at or after the Date of Grant, whenever any
            Option Price is paid in whole or in part by means of any of the
            forms of consideration specified in this Section 4(d), the Common
            Shares received upon the exercise of the Option Rights will be
            subject to such risks of forfeiture or restrictions on transfer as
            may correspond to any that apply to the consideration surrendered,
            but only to the extent, determined with respect to the consideration
            surrendered.

      (e)         To the extent permitted by law, any grant may provide for
            deferred payment of the Option Price from the proceeds of sale
            through a bank or broker on a date satisfactory to the Company of
            some or all of the shares to which such exercise relates.

      (f)         Successive grants may be made to the same Participant whether
            or not any Option Rights previously granted to such Participant
            remain unexercised.

      (g)         Each grant will specify the period or periods of continuous
            service by the Optionee with the Company or any Subsidiary that is
            necessary before the Option Rights or installments thereof will
            become exercisable and may provide for the earlier exercise of such
            Option Rights in the event of a Change in Control.

      (h)         Any grant of Option Rights may specify management objectives
            that must be achieved as a condition to the exercise of such rights.

      (i)         Option Rights granted under this Plan may be (i) options,
            including, without limitation, Incentive Stock Options, that are
            intended to qualify under

                                       4
<PAGE>

            particular provisions of the Code, (ii) options that are not
            intended so to qualify, or (iii) combinations of the foregoing.
            Incentive Stock Options may only be granted to Participants who meet
            the definition of "employees" under Section 3401(c) of the Code.

      (j)         The Board may, at or after the Date of Grant of any Option
            Rights (other than Incentive Stock Options), provide for the payment
            of dividend equivalents to the Optionee on either a current or
            deferred or contingent basis or may provide that such equivalents
            will be credited against the Option Price.

      (k)         No Option Right will be exercisable more than 10 years from
            the Date of Grant.

      (l)         The Board reserves the discretion after the Date of Grant to
            provide for (i) the payment of a cash bonus at the time of exercise;
            (ii) the availability of a loan at exercise; (iii) the right to
            tender in satisfaction of the Option Price nonforfeitable,
            unrestricted Common Shares, which are already owned by the Optionee
            and have a value at the time of exercise that is equal to the Option
            Price.

      (m)         Each grant of Option Rights will be evidenced by an Evidence
            of Award. Each Evidence of Award shall be subject to the Plan and
            shall contain such terms and provisions as the Board may approve.

5.          RESTRICTED SHARES. The Board may also authorize the grant or sale of
      Restricted Shares to Participants. Each such grant or sale may utilize any
      or all of the authorizations, and will be subject to all of the
      requirements, contained in the following provisions:

      (a)         Each such grant or sale will constitute an immediate transfer
            of the ownership of Common Shares to the Participant in
            consideration of the performance of services, entitling such
            Participant to voting, dividend and other ownership rights, but
            subject to the substantial risk of forfeiture and restrictions on
            transfer hereinafter referred to.

      (b)         Each such grant or sale may be made without additional
            consideration or in consideration of a payment by such Participant
            that is less than the Market Value per Share at the Date of Grant.

      (c)         Each such grant or sale will provide that the Restricted
            Shares covered by such grant or sale will be subject to a
            "substantial risk of forfeiture" within the meaning of Section 83 of
            the Code for a period of not less than two years, to be determined
            by the Board at the Date of Grant, and may provide for the earlier
            lapse of such substantial risk of forfeiture in the event of a
            Change in Control.

      (d)         Each such grant or sale will provide that during the period
            for which such substantial risk of forfeiture is to continue, the
            transferability of the Restricted Shares will be prohibited or
            restricted in the manner and to the extent prescribed by the Board
            at the Date of Grant (which restrictions may include, without
            limitation, rights of repurchase or first refusal in the Company or
            provisions

                                       5
<PAGE>

            subjecting the Restricted Shares to a continuing substantial risk of
            forfeiture in the hands of any transferee).

      (e)         Any grant of Restricted Shares may specify management
            objectives that, if achieved, will result in termination or early
            termination of the restrictions applicable to such shares.

      (f)         Any such grant or sale of Restricted Shares may require that
            any or all dividends or other distributions paid thereon during the
            period of such restrictions be automatically deferred and reinvested
            in additional Restricted Shares, which may be subject to the same
            restrictions as the underlying award.

      (g)         Each grant or sale of Restricted Shares will be evidenced by
            an Evidence of Award and will contain such terms and provisions,
            consistent with this Plan, as the Board may approve. Unless
            otherwise directed by the Board, all certificates representing
            Restricted Shares will be held in custody by the Company until all
            restrictions thereon will have lapsed, together with a stock power
            or powers executed by the Participant in whose name such
            certificates are registered, endorsed in blank and covering such
            Shares.

6.          DEFERRED SHARES. The Board may also authorize the granting or sale
      of Deferred Shares to Participants. Each such grant or sale may utilize
      any or all of the authorizations, and will be subject to all of the
      requirements contained in the following provisions:

      (a)         Each such grant or sale will constitute the agreement by the
            Company to deliver Common Shares to the Participant in the future in
            consideration of the performance of services, but subject to the
            fulfillment of such conditions during the Deferral Period as the
            Board may specify.

      (b)         Each such grant or sale may be made without additional
            consideration or in consideration of a payment by such Participant
            that is less than the Market Value per Share at the Date of Grant.

      (c)         Each such grant or sale will be subject to a Deferral Period
            of not less than 1 year, as determined by the Board at the Date of
            Grant, and may provide for the earlier lapse or other modification
            of such Deferral Period in the event of a Change in Control.

      (d)         During the Deferral Period, the Participant will have no right
            to transfer any rights under his or her award and will have no
            rights of ownership in the Deferred Shares and will have no right to
            vote them, but the Board may, at or after the Date of Grant,
            authorize the payment of dividend equivalents on such Shares on
            either a current or deferred or contingent basis, either in cash or
            in additional Common Shares.

                                       6
<PAGE>

      (e)         Each grant or sale of Deferred Shares will be evidenced by an
            Evidence of Award and will contain such terms and provisions,
            consistent with this Plan, as the Board may approve.

7.          TRANSFERABILITY.

      (a)         Except as otherwise determined by the Board, no Option Right
            or other derivative security granted under the Plan will be
            transferable by a Participant other than by will or the laws of
            descent and distribution. Except as otherwise determined by the
            Board, Option Rights will be exercisable during the Optionee's
            lifetime only by him or her or by his or her guardian or legal
            representative.

      (b)         The Board may specify at the Date of Grant that part or all of
            the Common Shares that are (i) to be issued or transferred by the
            Company upon the exercise of Option Rights or upon the termination
            of the Deferral Period applicable to Deferred Shares or (ii) no
            longer subject to the substantial risk of forfeiture and
            restrictions on transfer referred to in Section 5 of this Plan, will
            be subject to further restrictions on transfer.

8.          ADJUSTMENTS. The Board may make or provide for such adjustments in
      the numbers of Common Shares covered by outstanding Option Rights and
      Deferred Shares granted hereunder, in the Option Price, and in the kind of
      shares covered thereby, as the Board, in its sole discretion, exercised in
      good faith, may determine is equitably required to prevent dilution or
      enlargement of the rights of Participants that otherwise would result from
      (a) any stock dividend, stock split, combination of shares,
      recapitalization or other change in the capital structure of the Company,
      or (b) any merger, consolidation, spin-off, split- off, spin-out,
      split-up, reorganization, partial or complete liquidation or other
      distribution of assets, issuance of rights or warrants to purchase
      securities, or (c) any other corporate transaction or event having an
      effect similar to any of the foregoing. Moreover, in the event of any such
      transaction or event, the Board, in its discretion, may provide in
      substitution for any or all outstanding awards under this Plan such
      alternative consideration as it, in good faith, may determine to be
      equitable in the circumstances and may require in connection therewith the
      surrender of all awards so replaced. The Board may also make or provide
      for such adjustments in the numbers of shares specified in Section 3 of
      this Plan as the Board in its sole discretion, exercised in good faith,
      may determine is appropriate to reflect any transaction or event described
      in this Section 8; provided, however, that any such adjustment to the
      number specified in Section 3(c)(i) will be made only if and to the extent
      that such adjustment would not cause any Option intended to qualify as an
      Incentive Stock Option to fail so to qualify.

9.          CHANGE IN CONTROL. For purposes of this Plan, except as may be
      otherwise prescribed by the Board in an agreement evidencing a grant or
      award made under the Plan, a "Change in Control" shall mean the occurrence
      of any of the following events:

      (a)         The acquisition by any Person of beneficial ownership (within
            the meaning of Rule 13d-3 promulgated under the Exchange Act) of 35%
            or more of the Voting Power of the Company; provided, however, that
            for purposes of this

                                       7
<PAGE>

            Section 10(a), the following acquisitions shall not constitute a
            Change in Control: (i) any acquisition directly from the Company,
            (ii) any acquisition by the Company, (iii) any acquisition by any
            employee benefit plan (or related trust) sponsored or maintained by
            the Company, or (iv) any acquisition by any Person pursuant to a
            transaction which complies with clauses (i) and (ii) of Section
            9(c).

      (b)         A change in a majority of the members of the Board occurs: (i)
            within one year following the public announcement of an actual or
            threatened election contest (as described in Rule 14a-12(c)
            promulgated under the Exchange Act) or the filing of a Schedule 13D
            or other public announcement indicating that a Person intends to
            effect a change in control of the Company, (ii) as a result of the
            exercise of contractual rights, or (iii) as a result of a majority
            of the members of the Board having been proposed, designated or
            nominated by a Person (other than the Company through the Board or a
            committee of the Board).

      (c)         Consummation of a Business Combination unless, following such
            Business Combination, (i) no Person (excluding any entity resulting
            from such Business Combination or any employee benefit plan (or
            related trust) sponsored or maintained by the Company or such entity
            resulting from such Business Combination of either of them)
            beneficially owns, directly or indirectly, 35% or more of the Voting
            Power of the entity resulting from such Business Combination, and
            (ii) at least half of the members of the board of directors of the
            corporation resulting from such Business Combination were members of
            the Board at the time of the execution of the initial agreement, or
            of the action of the Board, providing for such Business Combination.

      (d)         Approval by the stockholders of the Company of a complete
            liquidation or dissolution of the Company.

      (e)         Such other event as the Board may determine by express
            resolution to constitute a Change in Control for purposes of this
            Plan.

10.         FRACTIONAL SHARES. The Company will not be required to issue any
      fractional Common Shares pursuant to this Plan. The Board may provide for
      the elimination of fractions or for the settlement of fractions in cash.

11.         WITHHOLDING TAXES. To the extent that the Company is required to
      withhold federal, state, local or foreign taxes in connection with any
      payment made or benefit realized by a Participant or other person under
      this Plan, and the amounts available to the Company for such withholding
      are insufficient, it will be a condition to the receipt of such payment or
      the realization of such benefit that the Participant or such other person
      make arrangements satisfactory to the Company for payment of the balance
      of such taxes required to be withheld, which arrangements (in the
      discretion of the Board) may include relinquishment of a portion of such
      benefit.

12.         FOREIGN EMPLOYEES. In order to facilitate the making of any grant or
      combination of grants under this Plan, the Board may provide for such
      special terms for

                                       8
<PAGE>

      awards to Participants who are foreign nationals or who are employed by
      the Company or any Subsidiary outside of the United States of America as
      the Board may consider necessary or appropriate to accommodate differences
      in local law, tax policy or custom. Moreover, the Board may approve such
      supplements to or amendments, restatements or alternative versions of this
      Plan as it may consider necessary or appropriate for such purposes,
      without thereby affecting the terms of this Plan as in effect for any
      other purpose, and the Secretary or other appropriate officer of the
      Company may certify any such document as having been approved and adopted
      in the same manner as this Plan. No such special terms, supplements,
      amendments or restatements, however, will include any provisions that are
      inconsistent with the terms of this Plan as then in effect unless this
      Plan could have been amended to eliminate such inconsistency without
      further approval by the shareholders of the Company.

13.         ADMINISTRATION OF THE PLAN.

      (a)         This Plan will be administered by the Board, which may from
            time to time delegate all or any part of its authority under this
            Plan to the Compensation Committee of the Board (or a subcommittee
            thereof), as constituted from time to time. A majority of the
            committee (or subcommittee) will constitute a quorum, and the action
            of the members of the committee (or subcommittee) present at any
            meeting at which a quorum is present, or acts unanimously approved
            in writing, will be the acts of the committee (or subcommittee). To
            the extent of any such delegation, references in this Plan to the
            Board will be deemed to be references to such committee or
            subcommittee.

      (b)         The interpretation and construction by the Board of any
            provision of this Plan or of any agreement, notification or document
            evidencing the grant of Option Rights, Restricted Shares or Deferred
            Shares and any determination by the Board pursuant to any provision
            of this Plan or of any such agreement, notification or document will
            be final and conclusive. No member of the Board will be liable for
            any such action or determination made in good faith.

14.         AMENDMENTS, ETC.

      (a)         The Board may at any time and from time to time amend the Plan
            in whole or in part; provided, however, that any amendment which
            must be approved by the shareholders of the Company in order to
            comply with applicable law or the rules of the Nasdaq Stock Market
            or, if the Common Shares are not traded on the Nasdaq Stock Market,
            the principal national securities exchange upon which the Common
            Shares are traded or quoted, will not be effective unless and until
            such approval has been obtained.

      (b)         The Board also may permit Participants to elect to defer the
            issuance of Common Shares or the settlement of awards in cash under
            the Plan pursuant to such rules, procedures or programs as it may
            establish for purposes of this Plan. The Board also may provide that
            deferred issuances and settlements include the payment or crediting
            of dividend equivalents or interest on the deferral amounts.

                                       9
<PAGE>

      (c)         The Board may condition the grant of any award or combination
            of awards authorized under this Plan on the surrender or deferral by
            the Participant of his or her right to receive a cash bonus or other
            compensation otherwise payable by the Company or a Subsidiary to the
            Participant.

      (d)         In case of termination of employment by reason of death,
            disability or normal or early retirement, or in the case of hardship
            or other special circumstances, of a Participant who holds an Option
            Right not immediately exercisable in full, or any Restricted Shares
            as to which the substantial risk of forfeiture or the prohibition or
            restriction on transfer has not lapsed, or any Deferred Shares as to
            which the Deferral Period has not been completed, or who holds
            Common Shares subject to any transfer restriction imposed pursuant
            to Section 7(b) of this Plan, the Board may, in its sole discretion,
            accelerate the time at which such Option Right may be exercised or
            the time at which such substantial risk of forfeiture or prohibition
            or restriction on transfer will lapse or the time when such Deferral
            Period will end or the time when such transfer restriction will
            terminate or may waive any other limitation or requirement under any
            such award.

      (e)         This Plan will not confer upon any Participant any right with
            respect to continuance of employment or other service with the
            Company or any Subsidiary, nor will it interfere in any way with any
            right the Company or any Subsidiary would otherwise have to
            terminate such Participant's employment or other service at any
            time.

      (f)         To the extent that any provision of this Plan would prevent
            any Option Right that was intended to qualify as an Incentive Stock
            Option from qualifying as such, that provision will be null and void
            with respect to such Option Right. Such provision, however, will
            remain in effect for other Option Rights and there will be no
            further effect on any provision of this Plan.

15.         GOVERNING LAW. The Plan and all grants and awards and actions taken
      thereunder shall be governed by and construed in accordance with the
      internal substantive laws of the State of Georgia.

16.         TERMINATION. No grant will be made under this Plan more than 10
      years after the date on which this Plan is first approved by the
      shareholders of the Company, but all grants made on or prior to such date
      will continue in effect thereafter subject to the terms thereof and of
      this Plan.

                                       10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00070-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00070-of-00352.parquet"}]]